Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has seen a nearly 6% increase, driven by positive forecasts regarding its business development agreements and expected revenue growth from partnerships with AstraZeneca and Madrigal Pharmaceuticals [1] Group 1: Business Development and Revenue Projections - According to a report from Citi, CSPC's business development transactions are expected to convert into recurring revenue starting in 2026 [1] - The agreements with AstraZeneca and Madrigal Pharmaceuticals are projected to bring approximately $10.2 billion in upfront and milestone payments, significantly boosting profits to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion for the fiscal years 2025 to 2027 [1] Group 2: Sales and Earnings Growth - CMB International noted that CSPC has signed six business development agreements since the end of 2024, establishing a pipeline with several late-stage or differentiated candidates that have high potential for external licensing [1] - The company's sales showed a slight recovery in Q3 of last year, with core revenue (excluding licensing income) increasing by 4.2% quarter-on-quarter, indicating a minor improvement in major products [1] - It is anticipated that the pharmaceutical sales will stabilize this year, with business development transactions expected to be a continuous driver of profit growth and support for dividends [1]
港股异动 | 石药集团(01093)涨近6% 机构预计BD交易将支持公司盈利及派息